ZYN002 Transdermal Gel Cannabidiol (CBD)
ZYN2-CL-017
Phase 3 small_molecule active
Quick answer
ZYN002 Transdermal Gel Cannabidiol (CBD) for Fragile X Syndrome (FXS) is a Phase 3 program (small_molecule) at Harmony Biosciences Holdings with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Harmony Biosciences Holdings
- Indication
- Fragile X Syndrome (FXS)
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active